Addressing the need to centrally regulate pharma

By Abhai Pandey,Lex Orbis IP Practice
0
1492
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Given the surge in research and development, amendments to the Patents Act, 1970, and the opening up of the market to foreign drug manufacturers, the pharmaceutical industry has been growing persistently.

It meets around 70% of the country’s demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. Being one of the key industries supporting the health sector, its regulation assumes critical importance.

New authority in the pipeline

The proliferation of spurious drugs and drugs with identical or similar sounding trade names has spurred the government to set up a Central Drug Authority of India to handle manufacturing approvals with the authority to sanction a certain brand name.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

Abhai Pandey is a lawyer with Lex Orbis IP Practice, a law firm specializing in intellectual property issues.

Lex_Orbis_logo-CMYK

709/710 Tolstoy House, 15-17 Tolstoy Marg

New Delhi – 110 001

India

Tel: +91 11 2371 6565

Fax: +91 11 2371 6556

Email: mail@lexorbis.com

www.lexorbis.com

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link